Celsion Corporation (CLSN) Trading Down 3.2%
Shares of Celsion Corporation (NASDAQ:CLSN) fell 3.2% on Monday . The company traded as low as $2.25 and last traded at $2.24. 838,108 shares were traded during trading, a decline of 74% from the average session volume of 3,228,840 shares. The stock had previously closed at $2.31.
A number of research firms have weighed in on CLSN. Maxim Group reaffirmed a “hold” rating on shares of Celsion Corporation in a research note on Tuesday, August 15th. Zacks Investment Research cut shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $12.63.
The firm’s market cap is $18.87 million. The firm has a 50 day moving average of $2.78 and a 200 day moving average of $1.76.
An institutional investor recently raised its position in Celsion Corporation stock. Renaissance Technologies LLC increased its holdings in Celsion Corporation (NASDAQ:CLSN) by 100.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,375,147 shares of the biotechnology company’s stock after purchasing an additional 690,349 shares during the quarter. Renaissance Technologies LLC owned 2.48% of Celsion Corporation worth $397,000 as of its most recent filing with the Securities & Exchange Commission. 7.46% of the stock is currently owned by institutional investors.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.